Switzerland· 55585004
Pegasys 180 mcg/0,5 ml, Injektionslösung in einer Fertigspritze
A peginterferon alfa-2a product, registered in Switzerland by CPS Cito Pharma Services GmbH and dispensed under Swissmedic category A. The same ATC class is registered in 14 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Peginterferon alfa-2a is registered in 14 of 19 countries.
Countries holding a registration under ATC L03AB11 (peginterferon alfa-2a), each read from that country’s own register.
- This record: Switzerland
- 9 of them publish a price we can compare per daily dose
Peginterferon alfa-2a · ATC L03AB11
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
- Manufacturer
- CPS Cito Pharma Services GmbH
- Country
- Switzerland (CH)
- ATC code
- L03AB11
- ATC class
- Peginterferon alfa-2a
- Defined daily dose
- 26 mcg, P
- Swissmedic category
- A
- Reimbursed
- No
- Last checked
- June 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
201 interactions on record for peginterferon alfa-2a.
Graded by severity as the source publishes them — 35 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Peginterferon alfa-2a · interactions on record
201 records
- 35 severe
- 163 moderate
- 3 minor
Most severe, free to view
- EltrombopagB02BX05severe
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- TelbivudineJ05AF11severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L03AB11
Peginterferon alfa-2a, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d53da203-8473-4c69-9e31-6a5a18604878 GET /v1/drugs/d53da203-8473-4c69-9e31-6a5a18604878?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Biotechnologika"
}See everything about peginterferon alfa-2a.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.